Alnylam is leading the translation of RNA interference (RNAi) into a whole class of innovative medicines, with the potential to help patients who have limited or inadequate treatment options live fuller, healthier lives.
We are delighted to exhibit at the British Society of Echocardiography's first fully virtual annual conference – we are particularly looking forward to Tuesday’s hypertrophic cardiomyopathy session and hearing the update to the BSE guidelines.
On our stand, you will have the opportunity to learn more about one patient’s journey to diagnosis by clicking on David’s story. For more information on diagnosing Hereditary ATTR Amyloidosis, click on the leaflet that summarises the red flags or the leave piece on a non-invasive method for diagnosing patients.
Our team will be available to contact throughout the meeting so please do visit our virtual stand and say hello! We look forward to interacting with you!
This content is published as part of a paid advertising agreement.